Sponsors (11)
The bill improves patient access to new dialysis drugs, CKD screening, and facility-based education while stabilizing provider payments, but does so by increasing Medicare spending and constraining payment flexibility — creating trade‑offs between access/quality and federal costs plus administrative and access risks if payments shift unfavorably.
Medicare beneficiaries receiving dialysis will have more reliable access to newly approved dialysis drugs because TDAPA payments are guaranteed for at least three years and a permanent post‑TDAPA add‑on is created, making coverage and reimbursement steadier.
Dialysis providers and facilities (hospitals, health systems) will receive higher and more predictable payments for dialysis services and for certain new drugs and education services, improving financial stability and reducing pressure on provider margins.
The bill ties payment updates to actual price changes and limits small, frequent adjustments (triggering only when forecast errors exceed 0.5 percentage points), which should reduce unpredictable, incremental payment swings for providers.
Taxpayers and the Medicare program face higher federal spending because the add‑on and separate payments are explicitly non‑budget neutral, which could increase Medicare Part B spending and put upward pressure on premiums or program solvency over time.
Narrowly defining 'renal dialysis services' risks excluding drugs for common comorbidities (e.g., diabetes, cardiovascular disease, cancer, obesity), which could shift costs or limit access to treatments important to many dialysis patients.
Mandating payment formulas and prohibiting case‑mix adjustments reduces CMS flexibility to tailor payments for patient complexity or local cost differences, potentially mispricing care for sicker or higher‑cost patient populations.
Based on analysis of 4 sections of legislative text.
Extends transitional add‑on payments and creates a permanent post‑TDAPA add‑on for qualifying dialysis drugs, adds CKD screening coverage, expands dialysis facility education, and adjusts ESRD payment update rules.
Introduced November 20, 2025 by Carol Devine Miller · Last progress November 20, 2025
Requires Medicare to extend transitional add-on payments and create a permanent add-on for certain new drugs and biologics used with renal dialysis, changes how dialysis payment updates are adjusted for forecasting errors, and adds Medicare coverage for chronic kidney disease (CKD) screening and expanded kidney disease education delivered by dialysis facilities. The bill sets effective dates (notably 2024 and 2026) and creates a new per-service post-transitional add-on payment formula that is non‑budget neutral, updates annual inflation indexing and forecasting rules, and directs CMS to implement billing modifiers and payment changes to accommodate these services.